Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1960 1
1963 1
1979 1
1997 2
1998 3
1999 3
2000 4
2001 4
2002 1
2003 2
2004 4
2005 3
2006 1
2007 5
2008 6
2009 6
2010 8
2011 5
2012 8
2013 7
2014 7
2015 6
2016 7
2017 6
2018 9
2019 11
2020 16
2021 14
2022 10
2023 10
2024 18
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
Gasperoni L, Giunta EF, Montanari D, Masini C, De Giorgi U. Gasperoni L, et al. Among authors: masini c. Expert Opin Drug Metab Toxicol. 2024 Jun;20(6):491-502. doi: 10.1080/17425255.2024.2353749. Epub 2024 May 22. Expert Opin Drug Metab Toxicol. 2024. PMID: 38778707 Free article. Review.
Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.
Samela T, Moretta G, Provini A, Pagnanelli G, Bonifati C, Graceffa D, Lora V, Orsini D, Zangrilli A, Giordano D, Dattola A, Richetta A, Bernardini N, Caldarola G, De Luca E, Masini C, Bavetta M, Tribuzi P, Panasiti V, Abeni D. Samela T, et al. Among authors: masini c. Dermatol Pract Concept. 2025 Apr 1;15(2):4644. doi: 10.5826/dpc.1502a4644. Dermatol Pract Concept. 2025. PMID: 40401857 Free PMC article.
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.
Iacovelli R, Ciccarese C, Buti S, Zucali PA, Fantinel E, Bimbatti D, Verzoni E, Accettura C, Bonomi L, Buttigliero C, Fornarini G, Pipitone S, Atzori F, Masini C, Massari F, Primi F, Strusi A, Giudice GC, Perrino M, Maruzzo M, Milella M, Giannarelli D, Brunelli M, Procopio G, Tortora G. Iacovelli R, et al. Among authors: masini c. Eur Urol. 2024 Nov;86(5):411-419. doi: 10.1016/j.eururo.2024.02.014. Epub 2024 Mar 22. Eur Urol. 2024. PMID: 38521617 Free article. Clinical Trial.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P, Cattrini C, Vitale MG, Rossi E, Mucciarini C, Rizzo M, Sisani M, Santoni M, Roviello G, Mollica V, Conteduca V, Grillone F, Cinausero M, Prati G, Atzori F, Stellato M, Massari F, Bersanelli M. Buti S, et al. Among authors: masini c. Ther Adv Urol. 2024 Apr 17;16:17562872241244574. doi: 10.1177/17562872241244574. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 38638242 Free PMC article.
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, Foglio F, Pinnavaia D, Ladisa V, Lauria Pantano C, Lerose R, Nardulli P, Ferraiuolo S, Maiolino P, De Stasio I, Gradellini F, Gasbarro AR, Santeramo R, Carrucciu G, Provasi R, Cirino M, Cappelletto PC, Fonzi E, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: masini c. Cancers (Basel). 2024 May 8;16(10):1802. doi: 10.3390/cancers16101802. Cancers (Basel). 2024. PMID: 38791882 Free PMC article.
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Baldo P, Orzetti S, Enrico F, Ladisa V, Lerose R, Nardulli P, Maiolino P, Gradellini F, Gasbarro AR, Carrucciu G, Provasi R, Cappelletto PC, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: masini c. Front Oncol. 2024 Mar 27;14:1351995. doi: 10.3389/fonc.2024.1351995. eCollection 2024. Front Oncol. 2024. PMID: 38601759 Free PMC article.
168 results